Investigating a new treatment for seizures using a specific inhibitor in mice
Testing the effects of a selective calpain-2 inhibitor on spontaneous recurrent seizures in mouse models of epilepsy
This study is looking at how a special treatment might help reduce seizures in mice with epilepsy, especially when the condition starts after injuries like strokes or head trauma, and it uses a method that could be easier and safer than current treatments.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Neuraegis, INC. NIH-funded |
| Lab location | 1 site (Irvine, UNITED STATES) |
| Project ID | NIH-11075014 on NIH RePORTER |
What this research studies
This research explores the effects of a selective calpain-2 inhibitor on spontaneous recurrent seizures in mouse models of epilepsy. The study aims to understand how this inhibitor can potentially prevent the progression of epilepsy, particularly in cases triggered by initial injuries like strokes or traumatic brain injuries. By using intranasal delivery for the treatment, the research seeks to enhance efficacy and reduce side effects compared to traditional methods. The findings could lead to new therapeutic strategies for managing epilepsy more effectively.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with epilepsy, particularly those who have experienced seizures following an initial brain injury.
Not a fit: Patients with epilepsy that is not linked to initial brain injuries or those who do not respond to calpain-2 inhibition may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a novel treatment that reduces seizure frequency and severity in patients with epilepsy.
How similar studies have performed: While the approach of using calpain inhibitors is promising, it is relatively novel and has not been extensively tested in human subjects for epilepsy treatment.
Where this research is happening
Irvine, UNITED STATES
- Neuraegis, INC. — Irvine, United States (Active)
Researchers
- Principal investigator: Baudry, Michel — Neuraegis, INC.
- Study coordinator: Baudry, Michel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.